摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4,6-bismethylthio-hexanoic acid | 5659-81-4

中文名称
——
中文别名
——
英文名称
4,6-bismethylthio-hexanoic acid
英文别名
4,6-Dimethylmercaptcaproic acid;BMHA;4,6-Bis(methylthio)hexanoic acid;4,6-bis(methylsulfanyl)hexanoic acid
4,6-bismethylthio-hexanoic acid化学式
CAS
5659-81-4
化学式
C8H16O2S2
mdl
——
分子量
208.346
InChiKey
YNCBLMJCJJLPEK-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.8
  • 重原子数:
    12
  • 可旋转键数:
    7
  • 环数:
    0.0
  • sp3杂化的碳原子比例:
    0.88
  • 拓扑面积:
    87.9
  • 氢给体数:
    1
  • 氢受体数:
    4

文献信息

  • [EN] DITHIOLAN-3-YLPENTANOATE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THE TREATMENT OF PAIN<br/>[FR] DÉRIVÉS DE DITHIOLAN-3-YLPENTANOATE, COMPOSITIONS PHARMACEUTIQUES ET MÉTHODES DE TRAITEMENT DE LA DOULEUR
    申请人:KRISANI BIOSCIENCES P LTD
    公开号:WO2015118554A1
    公开(公告)日:2015-08-13
    The disclosure herein provides 1-carbamoyloxyethyl 5-(1,2-dithiolan-3-yl)pentanoate derivatives of formula I, formula II and formula III. The disclosure also provides a method of synthesizing the compound of formula I, formula II and formula III. The compound of formula I, formula II and formula III or its pharmaceutical acceptable salts, as well as polymorphs, solvates, and hydrates, thereof may be formulated as pharmaceutical composition. The pharmaceutical composition of compound of formula I, formula II and formula III or the final compound of formula I, formula II or formula III may be formulated for non-invasive peroral, topical (example transdermal), enteral, transmucosal, targeted delivery, sustained release delivery, delayed release, pulsed release and parenteral methods. Such compositions may be used to treat chronic pain manifested with chronic diseases or its associated complications.
    本公开提供了式I、式II和式III的1-羰胺氧乙基5-(1,2-二环戊烷-3-基)戊酸酯生物。本公开还提供了一种合成式I、式II和式III化合物的方法。式I、式II和式III化合物或其药用可接受的盐,以及其多晶型、溶剂合物和合物,可制成药物组合物。式I、式II和式III化合物的药物组合物或式I、式II或式III的最终化合物可制成用于非侵入性口服、局部(例如经皮)、肠内、经粘膜、靶向递送、持续释放递送、延迟释放、脉冲释放和静脉途径的方法。这种组合物可用于治疗伴随慢性疾病或其相关并发症表现的慢性疼痛。
  • COMPOUND AND COMPOSITION AND THEIR USES THEREOF
    申请人:KANDULA MAHESH
    公开号:US20110218235A1
    公开(公告)日:2011-09-08
    A compound, composition, method of synthesizing and using the compound of formula 1 are disclosed. The compound of formula I also comprises of salts, polymorphs, solvates, and hydrates thereof. The compound may be formulated as pharmaceutical compositions. The pharmaceutical compositions may be formulated for peroral, topical, transmucosal, inhalation, targeted delivery and sustained release formulations. Such compositions may be used to treat hepatic and genetic disorders related to copper overload.
    揭示了一种化合物、组合物、合成和使用公式1的方法。公式I的化合物还包括其盐、多型体、溶剂合物和合物。该化合物可以制成药物组合物。药物组合物可以制成口服、局部、经粘膜、吸入、靶向递送和缓释制剂。这些组合物可用于治疗与超载相关的肝脏和遗传疾病。
  • BIOPASSIVATING MEMBRANE STABILIZATION BY MEANS OF NITROCARBOXYLIC ACID-CONTAINING PHOSPHOLIPIDS IN PREPARATIONS AND COATINGS
    申请人:Dietz Ulrich
    公开号:US20140099354A1
    公开(公告)日:2014-04-10
    The present invention relates to nitro-carboxylic acid (s)-containing phospholipids, to be used for coating of medical devices such as stents, catheter balloons, wound pads or surgical suture material and for bio-passivating compositions, such as rinses, waterproofing solutions, coating solutions, cryoprotection solutions, cold preservation media, lyoprotection solutions, contrast media solutions, preservation and reperfusion solutions containing these compounds as well as preparing solutions thereof and coating medical devices as well as their uses.
    本发明涉及一种含硝基羧酸(s)的磷脂,用于涂覆医疗器械,如支架、导管球囊、伤口垫或外科缝合材料,以及用于生物钝化组合物,如漱口液、防溶液、涂层溶液、冷冻保护溶液、冷藏介质、冻干保护溶液、造影介质溶液、含有这些化合物的保存和再灌注溶液,以及制备这些溶液和涂覆医疗器械以及它们的用途。
  • [EN] COMPOSITIONS AND METHODS FOR THE TREATMENT OF CHRONIC PAIN<br/>[FR] COMPOSITIONS ET PROCÉDÉS POUR LE TRAITEMENT D'UNE DOULEUR CHRONIQUE
    申请人:KANDULA MAHESH
    公开号:WO2013030692A1
    公开(公告)日:2013-03-07
    The disclosures herein provide compounds of formula (I) or its pharmaceutical acceptable salts, as well as polymorphs, enantiomers, stereoisomers, solvates, and hydrates thereof. These salts may be formulated as pharmaceutical compositions. The pharmaceutical compositions may be formulated for peroral administration, transdermal administration, transmucosal, syrups, topical, extended release, sustained release, or injection. Such compositions may be used to treatment of neurological disorders or conditions such as pain or its associated complications.
    本公开提供公式(I)或其药用可接受盐,以及其多晶型、对映体、立体异构体、溶剂合物和合物。这些盐可以制成药物组合物。药物组合物可以用于口服给药、经皮给药、经粘膜给药、糖浆、局部给药、延长释放、持续释放或注射。这些组合物可用于治疗神经系统疾病或疼痛及其相关并发症。
  • COMPOUND AND METHOD FOR THE TREATMENT OF PAIN
    申请人:KANDULA MAHESH
    公开号:US20110237658A1
    公开(公告)日:2011-09-29
    The disclosure herein provides a compound of formula 1. The disclosure also provides a method of synthesizing the compound of formula 1. The compound of formula 1 or its pharmaceutical acceptable salts, as well as polymorphs, solvates, and hydrates thereof may be formulated as pharmaceutical composition. The pharmaceutical composition of compound of formula 1 or the final compound may be formulated for non-invasive peroral, topical (example transdermal), enteral, transmucosal, targeted delivery, sustained release delivery, delayed release, pulsed release and parenteral methods. Such compositions may be used to treat chronic pain manifested with chronic diseases or its associated complications.
    本公开提供了一种化合物的化学式1。本公开还提供了一种合成该化合物的方法。化学式1的化合物或其药用可接受的盐,以及其多晶型、溶剂合物和合物可以制成药物组合物。化学式1的药物组合物或最终化合物可以制成用于非侵入性口服、局部(例如经皮)、肠内、经粘膜、靶向递送、持续释放递送、延迟释放、脉冲释放和静脉途径的方法。这些组合物可用于治疗伴随慢性疾病或其相关并发症表现的慢性疼痛。
查看更多

同类化合物

(甲基3-(二甲基氨基)-2-苯基-2H-azirene-2-羧酸乙酯) (±)-盐酸氯吡格雷 (±)-丙酰肉碱氯化物 (d(CH2)51,Tyr(Me)2,Arg8)-血管加压素 (S)-(+)-α-氨基-4-羧基-2-甲基苯乙酸 (S)-阿拉考特盐酸盐 (S)-赖诺普利-d5钠 (S)-2-氨基-5-氧代己酸,氢溴酸盐 (S)-2-[[[(1R,2R)-2-[[[3,5-双(叔丁基)-2-羟基苯基]亚甲基]氨基]环己基]硫脲基]-N-苄基-N,3,3-三甲基丁酰胺 (S)-2-[3-[(1R,2R)-2-(二丙基氨基)环己基]硫脲基]-N-异丙基-3,3-二甲基丁酰胺 (S)-1-(4-氨基氧基乙酰胺基苄基)乙二胺四乙酸 (S)-1-[N-[3-苯基-1-[(苯基甲氧基)羰基]丙基]-L-丙氨酰基]-L-脯氨酸 (R)-乙基N-甲酰基-N-(1-苯乙基)甘氨酸 (R)-丙酰肉碱-d3氯化物 (R)-4-N-Cbz-哌嗪-2-甲酸甲酯 (R)-3-氨基-2-苄基丙酸盐酸盐 (R)-1-(3-溴-2-甲基-1-氧丙基)-L-脯氨酸 (N-[(苄氧基)羰基]丙氨酰-N〜5〜-(diaminomethylidene)鸟氨酸) (6-氯-2-吲哚基甲基)乙酰氨基丙二酸二乙酯 (4R)-N-亚硝基噻唑烷-4-羧酸 (3R)-1-噻-4-氮杂螺[4.4]壬烷-3-羧酸 (3-硝基-1H-1,2,4-三唑-1-基)乙酸乙酯 (2S,4R)-Boc-4-环己基-吡咯烷-2-羧酸 (2S,3S,5S)-2-氨基-3-羟基-1,6-二苯己烷-5-N-氨基甲酰基-L-缬氨酸 (2S,3S)-3-((S)-1-((1-(4-氟苯基)-1H-1,2,3-三唑-4-基)-甲基氨基)-1-氧-3-(噻唑-4-基)丙-2-基氨基甲酰基)-环氧乙烷-2-羧酸 (2S)-2,6-二氨基-N-[4-(5-氟-1,3-苯并噻唑-2-基)-2-甲基苯基]己酰胺二盐酸盐 (2S)-2-氨基-N,3,3-三甲基-N-(苯甲基)丁酰胺 (2S)-2-氨基-3-甲基-N-2-吡啶基丁酰胺 (2S)-2-氨基-3,3-二甲基-N-(苯基甲基)丁酰胺, (2S)-2-氨基-3,3-二甲基-N-2-吡啶基丁酰胺 (2S,4R)-1-((S)-2-氨基-3,3-二甲基丁酰基)-4-羟基-N-(4-(4-甲基噻唑-5-基)苄基)吡咯烷-2-甲酰胺盐酸盐 (2R,3'S)苯那普利叔丁基酯d5 (2R)-2-氨基-3,3-二甲基-N-(苯甲基)丁酰胺 (2-氯丙烯基)草酰氯 (1S,3S,5S)-2-Boc-2-氮杂双环[3.1.0]己烷-3-羧酸 (1R,5R,6R)-5-(1-乙基丙氧基)-7-氧杂双环[4.1.0]庚-3-烯-3-羧酸乙基酯 (1R,4R,5S,6R)-4-氨基-2-氧杂双环[3.1.0]己烷-4,6-二羧酸 齐特巴坦 齐德巴坦钠盐 齐墩果-12-烯-28-酸,2,3-二羟基-,苯基甲基酯,(2a,3a)- 齐墩果-12-烯-28-酸,2,3-二羟基-,羧基甲基酯,(2a,3b)-(9CI) 黄酮-8-乙酸二甲氨基乙基酯 黄荧菌素 黄体生成激素释放激素(1-6) 黄体生成激素释放激素 (1-5) 酰肼 黄体瑞林 麦醇溶蛋白 麦角硫因 麦芽聚糖六乙酸酯 麦根酸